Company
bluebird bio, Inc.
Headquarters: Cambridge, MA, United States
Founded: April 16, 1992
Employees: 518
CEO: Mr. Andrew Obenshain
Market Cap
$76.5 Million
USD as of Jan. 1, 2025
bluebird bio, Inc. Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent à-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with à-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Financials
| Last Financial Reports Date | Sept. 30, 2023 |
| Revenue TTM | $21.7 M |
| EBITDA | $-131,774,000 |
| Gross Profit TTM | $-6,480,000 |
| Profit Margin | -180.15% |
| Operating Margin | -683.74% |
| Quarterly Revenue Growth | 17353.50% |
Stocks & Indices
bluebird bio, Inc. has the following listings and related stock indices.
Stock: NASDAQ: BLUE wb_incandescent
Stock: BMV: BLUE wb_incandescent
Stock: FSX: BLE wb_incandescent
Stock: Munich: BLE wb_incandescent
Product & Services
Zynteglo
Key People
Founder(s): Philippe Leboulch and Irving London
Nick Leschly, President & CEO Chip Baird, CFO